Quotient Sciences and Biorasi have established a partnership to expedite early phase clinical trials to patient proof of concept (PoC).
The collaboration merges Quotient Sciences’ early clinical development experience with Biorasi’s potential in participant recruitment globally, providing pharmaceutical and biotech sponsors with a streamlined pathway from investigational new drug application to PoC.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It ensures smooth transitions from healthy participants into subject groups within first-in-human (FIH) Phase I/IIa studies.
Sponsors will benefit from Quotient Sciences’ expertise in clinical pharmacology, which is backed by facilities in Miami, US, and Nottingham, UK, featuring a total of 230 beds, alongside a comprehensive database of trial subjects.
This is further enhanced by Biorasi’s extensive patient recruitment network covering a range of therapeutic areas including neurology, nephrology, dermatology and cell therapy.
Through the partnership, sponsors will gain access to a streamlined single-provider model for FIH to PoC programmes. This will include the option of a single contract, along with regulatory submissions and unified protocols, aimed at minimising outsourcing complexities and expediting development timelines.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataQuotient Sciences is enhancing its patient access framework by collaborating with both commercial and academic partners to address the industry’s growing demand for biomarker integration and patient assessments in FIH trials.
These hybrid protocols, which merge participant cohorts with healthy volunteers within an integrated design, provide scientific rigour and adaptability.
Quotient Sciences CEO Thierry Van Nieuwenhove said: “This partnership reflects our 35-year commitment to helping customers accelerate drug development to proof of concept by reducing complexity and breaking down traditional barriers.
“By combining Quotient’s clinical expertise with Biorasi’s global patient access network, we enable sponsors to efficiently conduct early-phase studies under a single operational and contracting model, while maintaining the highest standards of clinical research and data quality.”
